medigraphic.com

2015, Number 3

<< Back Next >>

Rev Mex Anest 2015; 38 (3)

Steroids in preeclampsia and microangiopathic hemolytic anemia

Viruez-Soto JA, Vallejo-Narváez CM, Briones-Garduño JC, Díaz de León-Ponce MA

Language: Spanish
References: 25
Page: 166-169
PDF size: 186.53 Kb.


ABSTRACT

The effort of an organized society to reduce maternal and perinatal morbimortality, is reflected in research and development of guides to support decisions about the most frequent diseases, including preeclampsia that in severe cases, can be associated with microangiopathic hemolytic anemia. Steroids are an essential tool in the management of this syndrome and because of many publications reporting different findings, a revision of the most important historic features and actual recommendations in the treatment with steroids is performed.


REFERENCES

  1. Katz L, Amorim M, Souza JP, Haddad SM, Cecatti JG and COHELLP Study Group. COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome. Reproductive Health. 2013;10:28.

  2. Pardo-Morales RV, Romero-Figueroa S, Vázquez-de Anda GF, Briones-Garduño JC, Herrera-Villalobos JE, González-Vargas A. Nueva alternativa terapéutica en preeclampsia severa. Cir Ciruj. 2004;72:203-207.

  3. Meneses-Calderón J, González-Carvajal NP, Gutiérrez-Morales H, Morales-González R, Briones Garduño JC. Microangiopatía trombótica y hemólisis intravascular (MTHI). Presentación de un caso. Rev Asoc Mex Med Crit y Ter Int. 2008;22:248-253.

  4. Díaz de León-Ponce MA, Briones-Garduño JC, Meneses-Calderón J, Moreno-Santillán AA. Microangiopatía trombótica y hemolysis intravascular en hipertensión por embarazo. La mentira del síndrome de HELLP. Cir Ciruj. 2006;74:211-215.

  5. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much as do about nothing? Am J Obstet Gynecol. 1990;162:311-316.

  6. Martin JN, Rinehart B, May W, Magann E, Terrone DA, Blake P. The spectrum of severe preeclampsia: Comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol. 1999;180:1373-1384.

  7. Herrera-Gallardo C. Corticoides en síndrome HELLP anteparto. Rev Obstet Ginecol Hosp. Santiago Oriente Dr. Luis Tisné Brousse. 2006;1:72-76.

  8. Sullivan CA, Magann EF, Perry KG, Roberts WE, Blake PG, Martin JN. The ocurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsecuent gestations. Am J Obstet Gynecol. 1994;171:940-943.

  9. Briones-Garduño JC, Guerrero-Hernández A, Díaz de León-Ponce M, Reyes-Mendoza JE, Briones-Vega CG. Ruptura hepática en preeclampsia. Rev Asoc Mex Med Crit y Ter Int. 2012;26:99-100.

  10. Díaz-Gallardo C. Mecanismos de acción de los fármacos inmunosupresores. Rev Chil Reumatol. 2008;24:73-88.

  11. Petersen K, Fuentes R, Lacassie HJ. Trombocitopenia y embarazo. Rev Chil Anestesia. 2006;35:165-171.

  12. Wallace K, Martin JN, Tam-Tam K, Wallukat G, Dechend R, Lamarca B, et al. Seeking the mechanism(s) of action for corticosteroids in HELLP syndrome: SMASH study. Am J Obstet Gynecol. 2013;208:1-8.

  13. Jank A, Schaarschmidt W, Stepan H. Effect of steroids on angiogenic factors in pregnant women with HELLP syndrome. J Perinat Med. 2011;39:611-613.

  14. Vigil-De Gracia P, García-Cáceres E. Dexamethasone in the pos-partum treatment of HELLP syndrome. International Journal of Gynecology and Obstetrics 1997; 59(3): 217-221.

  15. Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome: The benefit of corticosteroids. Am J Obstet Gynecol. 1999; 181: 304-309.

  16. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: Clinical issues and management. A Review. BMC Pregnancy and Childbirth 2009;9:8.

  17. Katz L, Ramos de Amorim MM, Verissimo-Miranda G, Pinto e Silva JL. Perfil clínico, laboratorial e complicações de pacientes com síndrome HELLP admitidas em uma unidade de terapia intensiva obstétrica. Rev Bras Ginecol Obstet. 2008;30:80-86.

  18. Martínez-Hernández E, González-Vargas A, Briones-Garduño JC. Comparación entre el tratamiento con dexametasona y el de metilprednisolona en pacientes con síndrome de HELLP. Arch Inv Mat Inf. 2010;2:25-29.

  19. Basaran A, Basaran M, Sen C. Choice of glucocorticoid en HELLP syndrome-dexamethasone versus betamethasone: revisiting the dilemma. J Matern Fetal Neonatal Med. 2012;25:2597-2600.

  20. Gutiérrez-Aguirre CH, Alatorre-Ricardo J, Cantú-Rodríguez O, Gómez-Almaguer D. Síndrome de HELLP, diagnóstico y tratamiento. Rev Hematol Mex. 2012;13:195-200.

  21. Magann E, Perry KG, Meydrech EF, Harris RL, Chauhan SP, Martin JN. Postpartum corticosteroids: Accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol. 1994;171:1154-1158.

  22. Mecacci F, Carignani L, Cioni R, Parretti E, Mignosa M, Piccioli A, et al. Time course of recovery and complications of HELLP syndrome with two different treatments: heparin or dexamethasone. Thromb Res. 2001;102:99-105.

  23. Tam-Tam KB, Keiser SD, Sims S, Brewer J, Owens MY, Martin JN. Antepartum eclampsia < 34 weeks case series: advisable to postpone delivery to administer corticosteroids for fetal pulmonary benefit? J Perinatol. 2011;31:161-165.

  24. Cararach-Ramoneda V, Botet-Mussons F. Preeclampsia, eclampsia y síndrome HELLP. Protocolos Diagnóstico Terapéuticos de la Asociación Española de Pediatría (AEP): Neonatología. Institut Clínic de Ginecologia, Obstetrícia i Neonatologia. Hospital Clínic de Barcelona. Barcelona 2008 [Última visita 27 de noviembre de 2014]. Disponible en: http://www.aeped.es/sites/default/files/documentos/16_1.pdf

  25. Martin JN. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynecol Obstet. 2013;121:202-207.




2020     |     www.medigraphic.com